Palvella Therapeutics (NASDAQ:PVLA) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report released on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $38.00 target price on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.12) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($2.62) EPS.

Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $12.00 on Thursday. The stock has a market capitalization of $15.84 million, a PE ratio of -0.99 and a beta of 0.61. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Insider Activity at Palvella Therapeutics

In other news, Director George M. Jenkins acquired 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the acquisition, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.39% of the company’s stock.